The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCVS Group Regulatory News (CVSG)

Share Price Information for CVS Group (CVSG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 967.00
Bid: 965.00
Ask: 971.00
Change: 6.00 (0.62%)
Spread: 6.00 (0.622%)
Open: 961.00
High: 972.00
Low: 950.00
Prev. Close: 961.00
CVSG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Options, PDMR Dealing and TVR

4 Jan 2022 07:00

RNS Number : 0520X
CVS Group plc
04 January 2022
 

4 January 2022

 

CVS Group Plc

("CVS", the "Company" or the "Group")

Exercise of Options, PDMR Dealing and Total Voting Rights

CVS, one of the UK's leading providers of integrated veterinary services, announces that on 4 January 2022, options over a total of 63,320 new ordinary shares of 0.2 pence each (the "New Shares") were exercised under the CVS Group 2018 SAYE Plan (2018/2021), at an exercise price of £8.30.

Richard Fairman, Chief Executive Officer, and Ben Jacklin, Chief Operating Officer, each exercised options over 737 ordinary shares of 0.2p in the Company ("Ordinary Shares"). The balance of the options were exercised by certain other employees and former employees of the Company.

Following their respective option exercises, Richard Fairman holds a beneficial interest in 29,462 Ordinary Shares in the Company, representing approximately 0.042 per cent of the total voting rights of the Company following the issue of the New Shares, and Ben Jacklin holds a beneficial interest in 5,446 Ordinary Shares in the Company, representing approximately 0.008 per cent of the total voting rights of the Company, calculated on the same basis.

Following the issue of the New Shares, the Company has a total issued share capital of 70,934,113 Ordinary Shares each carrying one voting right. The Company holds no Ordinary Shares in treasury. Therefore, following the issue of the New Shares, the total number of voting rights in the Company will be 70,934,113. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

This announcement is released by CVS Group plc and contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"), encompassing information relating to trading for the Company's current financial year, and is disclosed in accordance with the Company's obligations under UK MAR. This announcement is being made on behalf of the Company by the director named below.

 

Contacts:

CVS Group plc

via MHP Communications

Richard Fairman, CEO

 

Jenny Farrer, Company Secretary

 

Singer Capital Markets (Nominated Adviser & Broker)

+44 20 7496 3000

Aubrey Powell / Jen Boorer / Rachel Hayes

 

MHP Communications (Financial PR)

+44 20 3128 8549

Andrew Jaques / Rachel Mann / Charles Hirst

 

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Richard Fairman

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

CVS Group plc

b)

LEI

213800J41XDQ2NX48O05

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 0.2 pence each

 

GB00B2863827

b)

Nature of the transaction

Exercise of options under the 2018 SAYE Plan (1 January 2022 maturity)

 

c)

Price(s) and volume(s)

 

d)

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

N/A - single transaction

e)

Date of the transaction

4 January 2022

f)

Place of the transaction

London Stock Exchange

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Ben Jacklin

 

 

 

2

Reason for the notification

a)

Position/status

Chief Operating Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

CVS Group plc

b)

LEI

213800J41XDQ2NX48O05

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 0.2 pence each

 

GB00B2863827

b)

Nature of the transaction

 Exercise of options under the 2018 SAYE Plan (1 January 2022 maturity)

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

 

£8.30

737

 

 

 

 

 

 

 

d)

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

N/A - single transaction

e)

Date of the transaction

4 January 2022

f)

Place of the transaction

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEKBLBXFLLZFBF
Date   Source Headline
11th Apr 20245:48 pmRNSStandard form for notification of major holdings
8th Apr 20247:00 amRNSNotice of Cyber Incident
28th Mar 20244:07 pmRNSExercise of Options and Total Voting Rights
12th Mar 20248:06 amRNSResponse to CMA update
29th Feb 20247:00 amRNSExercise of Options and Total Voting Rights
29th Feb 20247:00 amRNSInterim Results
5th Feb 202411:02 amRNSStandard form for notification of major holdings
31st Jan 20247:00 amRNSExercise of Options and Total Voting Rights
29th Jan 20243:41 pmRNSPDMR Dealing
25th Jan 20247:00 amRNSHalf year Trading Update
19th Jan 20242:24 pmRNSExercise of SAYE Options and PDMR Dealing
12th Jan 20241:56 pmRNSExercise of SAYE Options and PDMR Dealing
12th Jan 20247:00 amRNSBlock Listing Interim Review
5th Jan 20242:44 pmRNSReplacement of Director/PDMR Shareholding
5th Jan 202410:25 amRNSDirector/PDMR Shareholding
29th Dec 20237:00 amRNSExercise of Options and Total Voting Rights
22nd Dec 20237:48 amRNSBlock Listing Application
30th Nov 20237:00 amRNSExercise of Options and Total Voting Rights
29th Nov 20233:43 pmRNSResult of AGM
29th Nov 20237:00 amRNSAGM Statement and Trading Update
24th Nov 20233:56 pmRNSGrant of Options under CVS Group plc
3rd Nov 20237:05 amRNSPosting of Annual Report and Notice of AGM
31st Oct 20234:46 pmRNSExercise of Options and Total Voting Rights
27th Oct 20237:00 amRNSDirectorate Change
13th Oct 20235:21 pmRNSConfirmation of dividend dates
9th Oct 20232:58 pmRNSExercise of Options, PDMR Dealing, EBT and TVR
29th Sep 20237:00 amRNSExercise of Options and Total Voting Rights
21st Sep 20237:00 amRNSFinal results for the year ended 30 June 2023
7th Sep 202310:50 amRNSResponse to CMA review into veterinary market
31st Aug 20237:00 amRNSExercise of Options and Total Voting Rights
31st Jul 20237:00 amRNSTotal Voting Rights
27th Jul 20237:00 amRNSTrading update, AU expansion and UK acquisitions
12th Jul 20237:00 amRNSBlock Listing Interim Review and TVR Update
30th Jun 20237:00 amRNSExercise of Options and Total Voting Rights
22nd Jun 20237:00 amRNSDirectorate Change
31st May 20237:00 amRNSExercise of Options and Total Voting Rights
12th May 20234:41 pmRNSStandard form for notification of major holdings
5th May 20238:53 amRNSBlock Listing Application
2nd May 20237:00 amRNSTotal Voting Rights
31st Mar 20231:39 pmRNSHolding(s) in Company
31st Mar 20237:00 amRNSTotal Voting Rights
10th Mar 202310:37 amRNSExercise of SAYE Options, PDMR Dealing and TVR
28th Feb 20237:00 amRNSExercise of Options and Total Voting Rights
24th Feb 20237:00 amRNSInterim Results
2nd Feb 20234:42 pmRNSExercise of Options and Total Voting Rights
26th Jan 20237:00 amRNSHalf year Trading Update
11th Jan 20234:31 pmRNSBlock Listing Interim Review and TVR Update
10th Jan 202312:24 pmRNSExercise of SAYE Options and PDMR Dealing
30th Dec 20227:00 amRNSExercise of Options and Total Voting Rights
20th Dec 20224:38 pmRNSExercise of Options and PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.